Monica M. Bertagnolli

Author

Also Known As

Bertagnolli, Monica M., Colacchio, Thomas A., D Morton, Goel, Ajay, Ian Tomlinson, Jewell, Scott D., Kroetz, Deanna L., Lerro, Catherine C., Liu, Geoffrey, M Bertagnolli

460

Publications

26.6K

Citations

H-Index

171

Concepts

All Affiliations

Brigham and Women's Hospital Dana-Farber Cancer Institute Harvard University Memorial Sloan Kettering Cancer Center Dana-Farber Brigham Cancer Center

About

Monica M. Bertagnolli is an author at Brigham and Women's Hospital specializing in medicine, cancer research, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	8	8	634
2	Engineering	2	2	396
3	Arts	1	1	195
4	Language Studies	1	1	195
5	Management	1	1	94

Monica M. Bertagnolli

148

Publications

23.6K

Citations

H-Index

Page 1

	Year	Citations
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq Itay Tirosh, Benjamin Izar, Sanjay M. Prakadan, Science Melanoma TumorsImmunologyBiological MicroenvironmentsTumor BiologyOncology	2016	5K
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention Scott D. Solomon, John J.V. McMurray, Marc A. Pfeffer, New England Journal of Medicine	2005	2K
Celecoxib for the Prevention of Sporadic Colorectal Adenomas Monica M. Bertagnolli, Craig Eagle, Ann G. Zauber, New England Journal of Medicine	2006	1K
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, JAMA	2017	852
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group Michael C. Heinrich, Kouros Owzar, Christopher L. Corless, Journal of Clinical Oncology	2008	649
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Susan K. Boolbol, Andrew J. Dannenberg, Amy Chadburn, PubMed Chemoprevention StrategyLipid PeroxidationApoptosisPathologyCell Death	1996	550
Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors Chandrajit P. Raut, Matthew Posner, Jayesh Desai, Journal of Clinical Oncology	2006	446
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, Journal of Clinical Oncology Calgb/swog 80405Kras Wild-typeLba3 BackgroundGastrointestinal OncologyMedicine	2014	403
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Joyce O’Shaughnessy, Gary J. Kelloff, Gary Gordon, PubMed PathologyCancer BiologyTumor BiologyCancer Cell BiologyRadiation Oncology	2002	383
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803 Monica M. Bertagnolli, Donna Niedzwiecki, Carolyn C. Compton, Journal of Clinical Oncology	2009	356

Page 1